Hostname: page-component-54dcc4c588-sdd8f Total loading time: 0 Render date: 2025-10-14T06:59:45.483Z Has data issue: false hasContentIssue false

Risk factors for treatment resistance among women with postpartum depression

Published online by Cambridge University Press:  26 August 2025

Y. Chen*
Affiliation:
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
D. Lu
Affiliation:
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Postpartum depression (PPD) impacts millions of new mothers worldwide, and the challenge of treatment resistance (TR) further hampers recovery prospects. The occurrence of TR in women with PPD and the risk factors for TR remain less studied. Identifying these factors is critical for the precise prediction of treatment responses, enabling tailored interventions and effective management of PPD.

Objectives

This study aimed to determine the prevalence of TR and assess risk factors associated with TR in women with PPD in a nationwide population-based setting.

Methods

We conducted a nationwide register-based cohort study of all women who gave birth during 2006-2021 in Sweden and were diagnosed with PPD up to 12 months postpartum. TR is defined as having ≥3 distinct antidepressant drugs, add-on medications, electroconvulsive therapy, or repetitive transcranial magnetic stimulation in one year after PPD diagnosis. Information on demographics, pregnancy characteristics and outcomes, comorbidities, and treatments were obtained from national registers. Potential risk factors in relation to TR were assessed using multivariable Poisson regression.

Results

Out of 58 618 women with PPD (mean age 30.8, SD 5.3), 4 933 (8.5%) occurred treatment resistance. Younger age (<20 vs. 25-29y: risk ratio (RR) 1.28, 95% CI 1.07-1.52), lower educational level (<9 vs. >12y: 1.52, 1.39-1.67), lower family income level (lowest 20% vs. top 20%: 1.28, 1.16-1.40), smoking at early pregnancy (≥10 cigarettes/day vs. no smoking: 1.39, 1.19-1.62), prior physical comorbidities (Charlson comorbidity index ≥2 vs. 0: 1.40, 1.18-1.65), prior psychiatric disorders (RRs for specific types range: 1.54-6.04) were significantly associated with treatment resistance. In contrast, non-primiparous patients had a reduced risk of treatment resistance (vs. primiparous women, RRs for 2 parities: 0.74, 0.69-0.79; ≥3 parities: 0.87, 0.80-0.95). Maternal body mass index, snuff use, delivery method, pregnancy outcomes, and hypertensive or diabetic disorders did not predict treatment resistance.

Conclusions

Treatment resistance in women with PD is common and is notably associated with specific demographic and clinical profiles. These findings highlight the need for personalized management strategies, particularly for identified high-risk groups.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.